Terbutaline
As of the edition of 20 October 2026, Terbutaline is a small molecule: marketed, first approved in 1975 (ES); acts on ADRB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1990
- Kind
- Small molecule
- Brand name
- Bricanyl
- First approved
- 1 April 1975 (ES)
- Approvals on record
- 11 in 4 regions
- Holder of the most recent approval
- AstraZeneca; 6 holders in all
- Registered trials
- 22, 3 stopped early
- Disease areas
- Immune system; Lungs and airways; Blood and lymph; Hormones; Nervous system; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 4 | 2 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 0 | 0 | 1 |
| Phase 3 | 5 | 4 | 0 | 1 |
| Phase 4 | 4 | 2 | 0 | 1 |
| All trials | 22 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Applicant and Lead sponsor of trials | 1990 to now |
| Novartis | Acquired holder | 2003 to now |
| Pharmacare | Acquired holder | 2016 to now |
| ANI Pharmaceuticals | Acquired holder | 2017 to now |
| GEIGY Pharmaceuticals | Later holder | |
| Sanofi | Applicant |